Importância das manifestações não motoras da Doença de Parkinson

Autores

  • Egberto Reis Barbosa Professor Livre Docente pelo Departamento de Neurologia da Faculdade de Medicina da Universidade de São Paulo. Coordenador do Grupo de Estudo de Distúrbios do Movimento da Clínica Neurológica do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
  • Luciano Magalhães Melo Médico Neurologista Colaborador do Grupo de Estudo de Distúrbios do Movimento da Clínica Neurológica do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

DOI:

https://doi.org/10.34024/rnc.2007.v15.8724

Palavras-chave:

Doença de Parkinson, Demência, Transtornos Psicóticos, Distúrbios do sono

Resumo

A doença de Parkinson (DP) é considerada essencialmente doença motora caracterizada por tremor de repouso, rigidez, bradicinesia, e distúrbios posturais. Entretanto, complicações não motoras, incluindo distúrbios do humor, ansiedade, fadiga, apatia, psicose, demência, distúrbios do sono e disfunção autonômica freqüentemente estão presentes nesta moléstia e têm impacto negativo na qualidade de vida dos pacientes e de seus cuidadores. O processo degenerativo próprio da DP, drogas utilizadas no tratamento da DP e reações emocionais frente à doença crônica, são as causas desses sintomas. Nesta revisão serão abordados as principais manifestações não motoras da DP

Métricas

Carregando Métricas ...

Downloads

Não há dados estatísticos.

Referências

Bronnick K, Aarsland D, Larsen JP. Neuropsychiatric disturbances in Parkinson’s disease clusters in five groups with different prevalence of dementia. Acta Psychiatr Scand 2005;112: 201–207.

Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Effect of Psychiatric and Other Nonmotor Symptoms on Disability in Parkinson’s Disease. J Am Geriatr Soc 2004;52:784-788.

Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, et al. ABN abstracts: The Association of British Neurologists Autumn Meeting, London, UK, 4–6 October 2006: Posters International validation of the first non motor questionnaire (NMSQuest) and scale (NMSS) for Parkinson’s disease. J Neurol Neurosurg Psychiatr 2007; 78:213.

Shulman LM, Taback RL, Bean J, Weiner WJ. Comorbidity of the nonmotor symptoms of Parkinson’s disease. Mov Disord 2001;16:507-510.

McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65:1863-1872.

de Lau LM, Schipper CM, Hofman A, Koudstaal PJ, Breteler MM. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. Arch Neurol 2005; 62:1265-1269.

Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatr 2000; 69:308-312.

Barbosa ER, Lefevre BH, Comerlatti LR, Scaff M, Canelas HM. Disfunções neuropsicológicas na doença de Parkinson. Estudo de 64 casos. Arq Neuropsiquiatr 1986; 44:55-59.

Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson’s disease: an 8-year prospective study. Arch Neurol 2003; 60:387-392.

Aarsland D, Bronnick K, Ehrt U, De Deyn PP, Tekin S, Emre M, et al. Neuropsychiatric symptoms in patients with Parkinson’s disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 2007;78:36–42.

Pluck CG, Brow RG. Apathy in Parkinson’s disease J. Neurol. Neurosurg. Psychiatry 2002;73;636-642.

Kirsch-Darrow L, Fernandez HF, Marsiske M, Okun MS. Dissociating apathy and depression in Parkinson disease. Neurology 2006;67:33–38.

Marder K, Cote L, Tang M. The risk and predictive factors associated with dementia in Parkinson’s disease. In: Korczyn A. Dementia in Parkinson’s Disease. Bologna: Monduzzi, 1994, p 51-54.

Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson’s disease: Progression to dementia. Mov Disord 2006; 21:1343-1349.

Huang X, Chen P, Kaufer DI, Troster AI, Poole C. Apolipoprotein E and dementia in Parkinson disease: a meta-analysis. Arch Neurol 2006; 63:189-193.

Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen P. Risk of dementia in Parkinson’s disease: A community–based, prospective study. Neurology 2001; 56:730-736.

Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease. A survey by the Canadian Movement Disorders Group. JAMA 2002;287:455–463.

,Woods SP, Troster AI. Prodromal frontal/executive dysfunction predicts incident dementia in Parkinson’s disease. J Int Neuropsychol Soc 2003;9:17-24.

Emre M. Dementia associated with Parkinson’s disease. Lancet Neurol 2003;2:229-237.

Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K, et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:996-1002.

Marinus J, Visser M, Verwey NA, Verhey FR, Middelkoop HA, Stiggelbout AM, et al. Assessment of cognition in Parkinson’s disease. Neurology. 2003; 61:1222-1228.

Mahieux F, Michelet D, Manifacier M, Boller F, Fermanian J, Guillard A. Minimental Parkinson: first validation study of a bedside test constructed for Parkinson’s disease. Behav Neurol 1995;8:15-22.

Klatka LA, Louis ED, Schiffer RB. Psychiatric features in diffuse Lewy body disease: A clinicopathologic study using Alzheimer’s disease and Parkinson’s disease comparison groups. Neurology 1996;47:1148-1152.

Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson’s disease. Curr Med Res Opin 2002; 18(5):258-264.

Ravina B, Putt M, Siderowf A, Farrar JT, Gillespie M, Crawley A, et al. Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study J Neurol Neurosurg Psychiatr 2005;76: 934–939.

Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson’s disease: a 8-year prospective study. Arch Neurol 2003;60:387-392.

Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004;351:2509-2518.

Poewe W, Wolters E, Emre M, Onofrj M, Hsu C, Tekin S, et al. Long-term benefits of rivastigmine in dementia associated with Parkinson’s disease: an active treatment extension study. Mov Disord. 2006;21:456-561.

Prado RCF, Barbosa ER. Depression in Parkinson’s Disease. Arq Neuropsiquiatr 2005;63:766-771.

Kostic VS, Filipovic SR, Lecic D, Momcilovic D, Sokic D, Sternic N. Effect of age at onset on frequency of depression in Parkinson’s disease. J Neurol Neurosurg Psychiatr 1994;57:1265-1257.

Starkstein SE, Petracca G, Chemerinski E, Teson A, Sabe L, Merello M, et al. Depression in classic versus akinetic-rigid Parkinson’s disease. Mov Disord 1998;13:29-33.

Rojo A, Aguilar M, Garolera MT, Cubo E, Navas I, Quintana S. Depression in Parkinson’s disease: clinical correlates and outcome Parkinsonism Relat Disord 2003;10:23-28.

Starkstein SE, Preziosi TJ, Bolduc PL, Robinson RG.Depression in Parkinson’s disease. J N Ment Dis 1990;178: 27-31.

McDonald WM, Richard IH, Delong MR. Prevalence, etiology, and treatment of depression in Parkinson’s disease. Biol Psychiatry 2003;54:363-375.

Lieberman A. Depression in Parkinson’s disease – a review. Acta Neurol Scand 2006;113:1–8.

Choi CH, Sohn YH, Kim JS. Depression in patients with Parkinson’s disease: A follow-up comparative study after long-term levodopa therapy. Mov Disord 1997;12(Suppl 1):125.

Barone P, Scarzella L, Marconi R, Antonini A, Morgante L, Bracco F, et al and the Depression/Parkinson Italian Study Group. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease. A national multicenter parallel-group randomized study. J Neurol 2006;253:601-607.

Weintraub D, Morales KH, Moberg PJ, Bilker WB, Balderston C, Duda JE, et al. Antidepressant studies in Parkinson´s disease: a review and metanalysis. Mov Disord 2005; 20:1161-1169.

Richard IH. Do serotonin reuptake inhibitor antidepressants worsen Parkinson´s disease? A retrospective case series. Mov Disord 1999;14:155-163.

Okun MS, Watts RL. Depression in Parkinson’s disease. Neurology 2002;58: S63-S70.

Fregni F, Santos CM, Myczkowski ML, Rigolino R, Gallucci-Neto J, Barbosa ER, et al. Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatr 2004; 75:1171-1174.

Voon V, Saint-Cyr JA, Lozano AM, Moro E, Dujardin K, Lang AE, et al. Suicide risk in patients with Parkinson’s disease undergoing subthalamic stimulation. Mov Disord. 2004;19(suppl9):S410-S411.

Burckard PR, Vingerhoets A, Berney A, Bogousslavsky J, Villemure JG, Ghika J. Death by suicide after deep brain stimulation. Mov Disord 2004;19(Suppl 9):S316.

Martinez-Martin P, Catalan MJ, Benito-Leon J, Moreno AO, Zamarbide I, Cubo E, et al. Impact of fatigue in Parkinson’s disease: the Fatigue Impact Scale for Daily Use (D-FIS). Qual Life Res 2006;15(4):597-606.

Alves G, Wentzel-Larsen T, Larsen JP. Is fatigue an independent and persistent symptom in patients with Parkinson disease? Neurology 2004;63:1908–1911.

Herlofson K, Larsen JP. The influence of fatigue on health-related quality of life in patients with Parkinson’s disease Acta Neurol Scand 2003:107:1–6.

Lou JS, Kearns G, Oken B, Sexton G, Nutt J. Exacerbates physical fatigue and mental fatigue in Parkinson’s disease. Mov Disord 2001;16:190-196.

Oved D, Ziv I, Treves TA, Paleacu D, Melamed E, Djaldetti R Effect of dopamine agonists on fatigue and somnolence in Parkinson’s disease. Mov Disord 2006;8:1257-1261.

Lou JS, Kearns G, Benice T, Oken B, Sexton G, Nutt J Levodopa improves physical fatigue in Parkinson’s disease: A double-blind, placebo-controlled, crossover study Mov Disord 2003; 10:1108-1114.

Fenelon G, MahieuX F, Huon R, Ziégler M. Hallutinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain 2000; 123:733-745.

Goetz CG, Wuu J, Curgian LM, Leurgans S. Hallucinations and sleep disorders in PD. Six-year prospective longitudinal study. Neurology 2005;64:81-86.

Graham JM, Grunwald RA, Sagar HJ. Hallucinations in idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatr 1997;63:434–440.

Barbosa ER, Limongi JCP, Cummings J. Parkinson’s disease. Psychiat Clin 1997;20:769-790.

Goetz CG, Pappert EJ, Blasucci LM, Stebbins GT, Ling ZD, Nora MV, et al. Intravenous levodopa in hallucinating Parkinson’s disease patients: high dose challenge does not precipitate hallucinations. Neurology 1998;50:515–517.

Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson disease. Arch Neurol 1996;53:1265-1268.

Fenelon G, Goetz CG, Karenberg A Hallucinations in Parkinson disease in the prelevodopa era . Neurology 2006;66:93–98.

Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M, The Celomen Study Group. Efficacy and safety of entacapone in Parkinson’s disease patients with suboptimal levodopa response: a 6-month randomised placebocontrolled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 2002;105:245–255.

Juncos JL. Management of psychotic aspects of Parkinson’s disease. J Clin Psychiatr 1999;60(Suppl 8):42-53.

Pollak P, Tison F, Rascol O, Destee A, Pere JJ, Senard JM, et al. Clozapine in drug induced psychosis in Parkinson’s disease: a randomized, placebo-controlled study with open follow up. J Neurol Neurosurg Psychiatr 2004;74:689-695.

Klein C, Gordon J, Pollak L, Rabey JM. Clozapine in Parkinson’s disease psychosis: 5-year follow-up review. Clin Neuropharmacol 2003, 26:8-11.

Reddy S, Factor SA, Molho ES, Feustel PJ. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord 2002;17:676-681.

Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson’s disease. Clin Pharmacol 2002;25:107-110.

Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson’s disease with dementia. Int J Geriatr Psychiatr 2003; 18(10):937-941.

Celesia GG, Barr AN. Psychosis and other psychiatric manifestations of levodopa therapy. Arch Neurol 1970;23 (3):193-200.

Goodwin FK. Psychiatric side effects of levodopa in man. JAMA 1971;218(13):1915-1920.

Evans AH, Lees AJ. Dopamine dysregulation syndrome in Parkinson’s disease Current Opinion in Neurology 2004;17:393–398.

Voon V, Thomsen T, Miyasaki JM, de Souza M, Shafro A, Fox SH, et al. Factors Associated With Dopaminergic Drug–Related Pathological Gambling in Parkinson DiseaseArch Neurol 2007;64:212-216.

Voon V, Hassan K, Zurowski M, Duff-Canning S. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 2006;66:1750–1752.

Askenasy JJ. Sleep in Parkinson’s Disease. Acta Neurol Scand 1993; 87:167–170.

Tandberg E, Larsen JP, Karlsen K. Excessive daytime sleepiness and sleep benefit in Parkinson’s disease: a community-based study. Mov Disord 1999;14:922–927.

Kumar S, Bhatia M, Behari M. Sleep disorders in Parkinson’s disease. Mov Disord 2002;7:775–781.

Brunner H, Wetter TC, Hogl B, Yassouridis A, Trenkwalder C, Friess E. Microstructure of the non-rapid eye movement sleep electroencephalogram in patients with newly diagnosed Parkinson’s disease: effects of dopaminergic treatment. Mov Disord 2002;17:928–993.

Adler CH, Thorpy MJ. Sleep issues in Parkinson’s disease. Neurology 2005;64: S12–S20.

Paus S, Brecht HM, Koster J, Seeger G, Klockgether T, Wullner U. Sleep attacks, daytime sleepiness,and dopamine agonists in Parkinson’ disease. Mov Disord 2003;18:659–667.

Arnulf I, Konofal E, Merino-Andreu M, Houeto JL, Mesnage V, Welter ML, Houeto JL, Mesnage V, Welter ML, et al. Parkinson’s disease and sleepiness - an integral part of PD. Neurology 2002;58:1019–1024.

Walsh K, Bennett G. Parkinson’s disease and anxiety Postgrad. Med J 2001;77:89-93.

Schiffer RB, Kurlan R, Rubin A, Boer S. Evidence for atypical depression in Parkinson’s disease. Am J Psychiatry 1988;145(8):1020-1022.

Maia AF, Pinto AS, Barbosa ER, Menezes PR, Miguel EC. Obssessive compulsive symptoms, obssessive compulsive disorder and related disorders in Parkinson’s disease. J Neuropsychiatr Clin Neurosci 2003;15:371-374.

Kurlan R. Repetitive behaviors in Parkinson’s disease. Mov Disord 2004;19: 433-469.

Olanow WC, Watts RL, William C, Koller WC. An algorithm (decision tree) for themanagement of Parkinson’sdisease (2001). Treat Guidelines 2001;56: S1-S88.

Nissenbaum H, Quinn NP, Brown RG, Toone B, Gotham AM, Marsden CD. Mood swings associated with the ‘‘on-off ’’ phenomenon in Parkinson’s disease. Psychol Med 1987;17:899–904.

Cantello R, Gilli M, Riccio A, Bergamasco B. Mood changes associated with ‘‘endof-dose deterioration’’ in Parkinson’s disease: a controlled study. J Neurol Neurosurg Psychiatr 1986;49:1182–1190.

Richard IH, Samuel Frank S, McDermott MP, Wang H, Justus AW, Ladonna KA, et al. The Ups and Downs of Parkinson Disease A Prospective Study of Mood and Anxiety Fluctuations. Cogn Behav Neurol 2004;17:201–207.

Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M, Pouget J, et al. Nonmotor fluctuations in Parkinson’s disease: frequent and disabling. Neurology 2002;59:408–413.

Stacy M, Bowron A, Guttman M, Hauser R, Hauser R, Hughes K, et al. Identification of Motor and nonmotor Wearing-off in Parkinson’s Disease: Comparison of a patient Questionnaire versus a Clinician assessment. Mov disord 2005;20:726-733.

Downloads

Publicado

2007-03-31

Como Citar

Barbosa, E. R., & Melo, L. M. (2007). Importância das manifestações não motoras da Doença de Parkinson. Revista Neurociências, 15(1), 51–60. https://doi.org/10.34024/rnc.2007.v15.8724

Edição

Seção

Revisão de Literatura

Artigos Semelhantes

1 2 3 4 5 6 7 8 9 10 > >> 

Você também pode iniciar uma pesquisa avançada por similaridade para este artigo.